BOKU - Universität für Bodenkultur Wien - Forschungsinformationssystem

Logo BOKU-Forschungsportal

Gewählte Publikation:

Benedetti, F; Stadlbauer, K; Stadlmayr, G; Rueker, F; Wozniak-Knopp, G.
(2021): A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
LIFE-BASEL. 2021; 11(11), 1157 FullText FullText_BOKU

Abstract:
The overexpression of tyrosine kinase HER2 in numerous cancers, connected with fierce signaling and uncontrolled proliferation, makes it a suitable target for immunotherapy. The acquisition of resistance to currently used compounds and the multiplicity of signaling pathways involved prompted research into the discovery of novel binders as well as treatment options with multiple targeting and multispecific agents. Here we constructed an anti-HER2 tetravalent and biparatopic symmetrical IgG-like molecule by combining the Fab of pertuzumab with a HER2-specific Fcab (Fc fragment with antigen binding), which recognizes an epitope overlapping with trastuzumab. In the strongly HER2-positive cell line SK-BR-3, the molecule induced a rapid and efficient reduction in surface HER2 levels. A potent anti-proliferative effect, specific for the HER2-positive cell line, was observed in vitro, following the induction of apoptosis, and this could not be achieved with treatment with the mixture of pertuzumab and the parental Fcab. The inhibitory cytotoxic effect of our antibody as a single agent makes it a promising contribution to the armory of anti-cancer molecules directed against HER2-addicted cells.
Autor*innen der BOKU Wien:
Benedetti Filippo
Rüker Florian
Stadlbauer Katharina
Stadlmayr Gerhard
Wozniak-Knopp Gordana
BOKU Gendermonitor:


Find related publications in this database (Keywords)
biparatopic targeting
bispecific antibodies
Fcab
HER2 internalization
HER2 overexpression
mAb(2)
pertuzumab
trastuzumab


Altmetric:
© BOKU Wien Impressum